Trimetazidine Shows Promise in Treating Metabolic Dysfunction-Associated Steatotic Liver Disease

Can Trimetazidine Revolutionize MASLD Treatment?

The treatment landscape for metabolic dysfunction-associated steatotic liver disease (MASLD) has received a promising addition, according to results from a recent randomized clinical trial investigating the effects of trimetazidine (TMZ) on liver health markers. This 24-week, double-blind, placebo-controlled study conducted at Beni-Suef University Hospital enrolled 60 patients with confirmed MASLD, demonstrating significant improvements in hepatic steatosis, inflammatory markers, and lipid profiles among participants receiving TMZ compared to placebo.

MASLD, formerly known as non-alcoholic fatty liver disease (NAFLD), represents the most prevalent form of chronic liver disease globally, affecting approximately 25% of the world's population. The condition is characterized by excessive fat accumulation in the liver, inflammation, and potential progression to fibrosis. Approximately one-quarter of MASLD patients develop metabolic dysfunction-associated steatohepatitis (MASH), which significantly increases the risk of cirrhosis, hepatocellular carcinoma, and liver failure. The disease's close association with metabolic disorders, including obesity, type 2 diabetes, hypertension, and dyslipidemia, has prompted researchers to explore metabolic modulators as potential therapeutic agents. In this context, trimetazidine, a medication historically used for angina pectoris, has emerged as a candidate therapy due to its inhibition of fatty acid oxidation and potential anti-inflammatory properties.

How Was This Study Conducted?

The trial methodology involved randomizing participants in a 1:1 ratio to receive either trimetazidine 20 mg orally three times daily (total 60 mg/day) or a visually identical placebo. Both groups received standardized lifestyle modification guidance. Participants underwent comprehensive baseline assessments, including detailed medical history, physical examination, laboratory investigations, and non-invasive liver fibrosis and steatosis measurements using transient elastography (FibroScan) with controlled attenuation parameter (CAP). Various non-invasive fibrosis indices were calculated, including the AST-to-platelets ratio index (APRI), Fibrosis-4 index (FIB-4), NAFLD fibrosis score, atherosclerotic cardiovascular disease score (ASCVD), and the fibrosis to AST score (FAST). Inflammatory markers assessed included tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and high-sensitivity C-reactive protein (hs-CRP).

What Clinical Improvements Were Observed?

After 24 weeks of treatment, the trimetazidine group demonstrated significant improvements in multiple parameters compared to the placebo group. Most notably, the CAP score, which quantifies hepatic steatosis, showed significant reduction (p < 0.001), indicating meaningful improvement in liver fat content. Liver inflammation, as measured by TNF-α levels, also decreased significantly (p = 0.001) in the trimetazidine group compared to placebo. Regarding liver enzymes, aspartate aminotransferase (AST) levels decreased significantly in the trimetazidine group (p < 0.001), with a significant between-group difference (p = 0.032). These findings suggest that trimetazidine effectively addresses multiple aspects of MASLD pathophysiology, including steatosis, inflammation, and hepatocellular injury.

The lipid-lowering effects of trimetazidine were equally impressive, with significant reductions in both total cholesterol (p = 0.004) and low-density lipoprotein (LDL) cholesterol (p = 0.004) compared to placebo. However, no significant changes were observed in high-density lipoprotein (HDL) cholesterol or triglyceride levels, suggesting a selective effect on certain lipid fractions. Interestingly, the metabolic parameters, including fasting blood glucose and homeostatic model assessment for insulin resistance (HOMA-IR), remained relatively stable throughout the study period, indicating that trimetazidine's beneficial effects on liver health may occur independently of improvements in insulin sensitivity. Importantly, no significant adverse effects were reported during the 24-week treatment period, supporting the safety profile of trimetazidine in this patient population.

How Does Trimetazidine Stack Up Against Other Treatments?

These findings align with previous preclinical and limited clinical evidence suggesting hepatoprotective effects of trimetazidine. Animal studies have demonstrated that TMZ can reduce hepatocyte steatosis, attenuate fibrosis, and protect against liver damage in various experimental models. The anti-inflammatory effect observed in this trial, particularly the reduction in TNF-α, is consistent with trimetazidine's known mechanisms, which include inhibition of fatty acid β-oxidation, promotion of glucose oxidation, and modulation of inflammatory pathways. The lipid-lowering profile observed—reductions in total and LDL cholesterol without significant changes in HDL or triglycerides—also matches patterns seen in earlier studies of shorter duration, suggesting that longer treatment periods or combination therapy might be necessary to affect all lipid parameters.

When positioned among emerging therapies for MASLD, trimetazidine offers a unique profile. Unlike glucagon-like peptide-1 receptor agonists (GLP-1 RAs) or sodium-glucose cotransporter-2 (SGLT2) inhibitors, which improve hepatic outcomes primarily through weight loss and glycemic control, trimetazidine appears to act directly on liver metabolism without substantial weight change. This offers a potential alternative or adjunctive option for patients who may not tolerate these other therapies or in whom weight loss is challenging. Similarly, while pioglitazone has shown histological benefits in MASLD, its association with weight gain and fluid retention limits its applicability in many patients. Trimetazidine's favorable safety profile and specific effects on liver fat, inflammation, and fibrosis suggest it could fill an important gap in the therapeutic armamentarium for MASLD.

What Are the Study's Limitations and Future Directions?

Despite these promising results, the study has several limitations worth noting. The relatively small sample size (30 patients per group) and single-center design may limit generalizability. The reliance on non-invasive markers rather than liver biopsy, while ethically appropriate, prevents definitive histological confirmation of improvement. Additionally, despite randomization, there were baseline imbalances in some parameters, including ALT levels, FAST scores, and TNF-α concentrations, which required statistical adjustment through ANCOVA analysis. The 24-week duration, while sufficient to demonstrate significant changes, may not reflect long-term efficacy or safety. These limitations underscore the need for larger, multicenter trials with extended follow-up periods to confirm these findings and explore optimal dosing strategies.

The implications of this research extend beyond the immediate findings. As MASLD affects up to one-quarter of the global population and lacks approved pharmacological treatments, identifying effective therapies represents a critical unmet need. Trimetazidine's mechanism of action—targeting metabolic pathways directly in the liver—offers a novel approach that could complement existing strategies focused on weight management and glycemic control. Could this metabolic modulator become part of a multi-faceted approach to MASLD, perhaps in combination with lifestyle interventions or other pharmacological agents? What subgroups of patients might benefit most from its unique mechanism of action? These questions highlight important directions for future research in this rapidly evolving field.

Could This Data Change Current MASLD Management?

Could the introduction of trimetazidine into clinical practice shift current treatment paradigms for MASLD, particularly for patients with contraindications to weight loss medications or those who fail to respond to lifestyle modifications alone? What role might combination therapies play in addressing the complex pathophysiology of MASLD, and how might trimetazidine complement other emerging treatments targeting different disease pathways? As we await larger confirmatory trials, these questions invite reflection on the evolving approach to this increasingly prevalent condition and the potential for metabolic modulators like trimetazidine to address a significant unmet medical need in hepatology.

Summary

A recent randomized clinical trial at Beni-Suef University Hospital investigated trimetazidine's effects on MASLD patients over 24 weeks. The study of 60 participants showed significant improvements in hepatic steatosis, inflammatory markers, and lipid profiles in the treatment group. Patients receiving TMZ (20 mg three times daily) demonstrated reduced CAP scores, decreased TNF-α levels, and improved AST levels compared to placebo. The treatment also lowered total and LDL cholesterol levels while maintaining a favorable safety profile. While promising, the study's limitations, including small sample size and single-center design, suggest the need for larger, multicenter trials to confirm these findings and explore optimal dosing strategies.